3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Sarcoma, Clear Cell
2
Sarcoma
2
Neurofibrosarcoma
2
Nerve Sheath Neoplasms
2
Liposarcoma
2
Histiocytoma, Angiomatoid Fibrous
2
Granuloma, Plasma Cell
2
Fibrosarcoma
2
Dermatofibrosarcoma
2
Chondrosarcoma, Extraskeletal Myxoid
2
Carcinoma, Renal Cell
2
Vascular Neoplasms
1
Solitary Fibrous Tumors
1
Smooth Muscle Tumor
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Perivascular Epithelioid Cell Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasms, Adipose Tissue
1
Myoepithelioma
1
Liposarcoma, Myxoid
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
Granular Cell Tumor
1
Glomus Tumor
1
Glioblastoma
1
Interventions
Temozolomide
18
Radiotherapy
11
Magnetic Resonance Spectroscopy
11
Specimen Handling
8
Radiation
7
Lomustine
4
Nivolumab
3
Biopsy
3
trametinib
2
rocakinogene sifuplasmid
2
dabrafenib
2
cemiplimab
2
Receptors, Interleukin-8B
2
Photons
2
Palliative Care
2
Ipilimumab
2
CTLA-4 Antigen
2
vocimagene amiretrorepvec
1
veliparib
1
varlilumab
1
tinostamustine
1
temsirolimus
1
senicapoc
1
selinexor
1
relatlimab
1
regorafenib
1
perampanel
1
peposertib
1
pembrolizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
pazopanib
×
30 days
×
Clear all
NCT02331498
2026-05-06
PAZOGLIO
Centre Antoine Lacassagne
Phase 1/2
Active not recruiting
51 enrolled